| Literature DB >> 33682447 |
Ajay K Nooka1, Katja Weisel2, Niels Wcj van de Donk3, David Routledge4, Paula Rodriguez Otero5, Kevin Song6, Hang Quach7, Natalie Callander8, Monique C Minnema9, Suzanne Trudel10, Nicola A Jackson11, Christoph M Ahlers12, Ellie Im13, Shinta Cheng14, L Smith14, Nahi Hareth15, Geraldine Ferron-Brady12, Maria Brouch12, Rocio Montes de Oca12, Sofia Paul12, Beata Holkova12, Ira Gupta12, Brandon E Kremer13, Paul Richardson16.
Abstract
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).Entities:
Keywords: BCMA; GSK3174998; antibody–drug conjugate; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; multiple myeloma; nirogacestat; platform study
Mesh：
Substances：
Year: 2021 PMID： 33682447 DOI： 10.2217/fon-2020-1269
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404